BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update. To access the live ...

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit pro ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Atea Pharmaceuticals is presenting updates on its clinical programs for hepatitis C and hepatitis E at the 44th Annual JPMorgan Healthcare Conference [1][2]. Group 1: Hepatitis C Program - The company is executing a global Phase III program for the treatment of hepatitis C, with a pivotal year anticipated in 2026 [3]. - Bemnifosbuvir, discovered seven years ago, is nearing the completion of its first trial, C-BEYOND, which has enrolled over 900 patients [3]. - Results from the C-BEYOND trial are expected in mid-2026, specifically in Q3 [3]. Group 2: Hepatitis E Program - Atea Pharmaceuticals is also advancing a new program for the treatment of hepatitis E, although specific details on this program were not elaborated in the provided text [2].

Atea Pharmaceuticals Conference Call Summary Company Overview - **Company**: Atea Pharmaceuticals (NasdaqGS:AVIR) - **Event**: FY Conference on January 15, 2026 - **Focus**: Updates on bemnifosbuvir and ruzasvir for Hepatitis C treatment and new Hepatitis E program Key Points on Hepatitis C Treatment - **Phase 3 Program**: Atea is executing a global phase 3 program for Hepatitis C, with pivotal data expected in mid-2026 [2][3] - **Enrollment**: Over 900 patients enrolled in the North American trial, with completion expected by the end of Q2 2026 [3][4] - **NDA Filing**: Anticipated filing of a New Drug Application (NDA) with the FDA in Q1 2026 [4] - **Efficacy**: The regimen shows a 98% efficacy cure rate in phase 2 studies, with a focus on a short treatment duration of 8 weeks [9][32] - **Market Dynamics**: Despite the introduction of effective treatments, the number of Hepatitis C infections in the U.S. has increased from 2.5 million to over 4 million in the last decade [6][28] - **Commercial Opportunity**: The global Hepatitis C market is approximately $3 billion, with the U.S. accounting for about 50% [34] Insights on Hepatitis E Program - **Target Population**: Focus on immunocompromised patients, particularly those undergoing solid organ transplants [4][22] - **Market Potential**: Estimated 450,000 patients annually in the U.S. and Europe, with a potential billion-dollar market opportunity [23] - **Treatment Development**: Atea is advancing a new candidate, 80587, for Hepatitis E, with IND-enabling studies underway [21][25] Financial Position - **Cash Reserves**: Atea has over $300 million in cash and investments, providing a runway through 2027-2028 [5] - **Cost of Goods**: Anticipated low single-digit costs related to net pricing, with expectations for profitability within 24 months post-launch [21] Industry Context - **Infection Trends**: The opioid crisis has contributed to a rising number of Hepatitis C infections, with an estimated 160,000 new infections annually in the U.S. [28] - **Test-and-Treat Model**: A proposed model to enhance screening and treatment access, particularly for younger populations at risk [30][31] Regulatory and Clinical Considerations - **Regulatory Strategy**: Atea is preparing for potential differences in regulatory requirements between the FDA and EMA [17][19] - **Clinical Trial Design**: Emphasis on robust trial designs to ensure sufficient power and efficacy comparisons against standard treatments [19][20] Conclusion - **Pivotal Year**: 2026 is positioned as a critical year for Atea, with significant milestones in both Hepatitis C and E programs expected [26][27]

HCV Program (BEM/RZR) - The company is developing BEM/RZR as a potential best-in-class treatment for HCV, with Phase 3 trials underway[7, 12] - Phase 2 results showed a 98% sustained virologic response (SVR12) with the BEM/RZR combination regimen[12] - Two Phase 3 trials, C-BEYOND (US/Canada) and C-FORWARD (outside North America), are enrolling approximately 1,760 patients in total[12, 30] - The US sees over 160 thousand new chronic HCV infections annually, while approximately 90 thousand are treated, highlighting the need for improved treatment strategies[18] - Market research indicates that 48% of non-cirrhotic patients and 49% of compensated cirrhotic patients are likely to be prescribed BEM/RZR[21] HEV Program (AT-587) - A new program is focused on Hepatitis E Virus (HEV) with product candidate AT-587, targeting Phase 1 initiation in mid-2026[7] - The WHO estimates up to 20 million global HEV infections annually[42] - Approximately 3% of at-risk patients develop chronic HEV, leading to a potential treatment population of ~135 thousand patients annually[51] - The commercial opportunity for HEV treatment in the US & EU is estimated at $750 million to $1 billion[50, 51] - AT-587 demonstrates potent antiviral activity against multiple HEV-3 strains and ribavirin-resistant virus[53] Financial Status - The company reported cash and investments of $3018 million as of December 31, 2025, with a cash runway anticipated through 2027[7, 61]

Financial Position - Atea Pharmaceuticals ended 2025 with cash and investments totaling $301.8 million, providing a cash runway expected to extend through 2027[1]. Clinical Trials and Development - The global Phase 3 program for the HCV treatment regimen of bemnifosbuvir (BEM) and ruzasvir (RZR) includes over 880 patients in the C-BEYOND trial, with topline results expected in mid-2026[7]. - The C-FORWARD trial outside North America is expected to complete enrollment by mid-2026, with topline results anticipated by year-end 2026[7]. - In a Phase 2 study, the 8-week regimen of BEM/RZR achieved a 98% sustained virologic response (SVR12) in the per-protocol population[10]. - Atea's new product candidate AT-587 for Hepatitis E virus (HEV) is anticipated to enter Phase 1 clinical trials in mid-2026, addressing a significant unmet need[5][14]. Market Opportunity - The potential market opportunity for the HEV program is estimated to be between $750 million and $1 billion in the US and EU[15]. - The global HCV market is estimated at approximately $3 billion in net sales annually, with about $1.5 billion attributed to the US[13]. Product Profile and Strategy - Atea's regimen of BEM/RZR is designed to have high efficacy, short treatment duration, and low risk of drug-drug interactions, aligning with the needs of HCV patients[4][12]. - Independent market research indicates strong provider interest in a new HCV treatment option with the profile of the BEM/RZR regimen[11]. - Atea aims to build a diversified antiviral portfolio, with HCV as the lead development pillar and HEV as a strategic expansion[16].

Core Insights - Atea Pharmaceuticals is advancing its global Phase 3 program for a potential best-in-class regimen for Hepatitis C virus (HCV) treatment, with topline results expected in mid-2026 from the C-BEYOND trial in North America and by year-end 2026 from the C-FORWARD trial outside North America [1][6][16] - The company is also initiating a Phase 1 clinical program for its Hepatitis E virus (HEV) product candidate AT-587, anticipated to start in mid-2026 [1][3][12] HCV Treatment Program - The regimen under evaluation consists of bemnifosbuvir (BEM), a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir (RZR), an HCV NS5A inhibitor, aimed at addressing challenges with current HCV therapeutics [2][5] - C-BEYOND has over 880 patients fully enrolled, while C-FORWARD is expected to complete enrollment by mid-2026 [6] - The primary endpoint for both trials is achieving HCV RNA below the lower limit of quantitation (LLOQ) at 24 weeks, assessing sustained virologic response 12 weeks post-treatment (SVR12) [7] Market Potential and Provider Insights - The global HCV market is estimated at approximately $3 billion in net sales annually, with about $1.5 billion attributed to the US [11] - A survey of healthcare providers indicated a strong demand for a new treatment option that offers high efficacy, short treatment duration, and low risk of drug-drug interactions (DDIs), as many HCV patients are on multiple medications [10][11] HEV Program Development - Atea's new HEV program targets a significant unmet medical need, particularly for immunocompromised patients, with AT-587 selected as the lead candidate showing potent antiviral activity against HEV [12][13] - The potential market opportunity for HEV treatment in the US and EU is estimated between $750 million to $1 billion [13] Strategic Outlook - Atea aims to build a diversified antiviral portfolio, with HCV as the lead development pillar and HEV as a strategic expansion [14] - The company is focused on disciplined execution and resource deployment to maximize clinical and commercial potential [14][16]

Core Viewpoint - Atea Pharmaceuticals, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, highlighting its focus on oral antiviral therapeutics for serious viral diseases [1]. Company Overview - Atea Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing oral antiviral therapies to meet the unmet medical needs of patients with serious viral infections [3]. - The company utilizes a proprietary nucleos(t)ide prodrug platform to develop novel product candidates targeting single-stranded ribonucleic acid (ssRNA) viruses, which are significant contributors to serious viral diseases [3]. - Atea's lead program involves a regimen combining bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, aimed at treating Hepatitis C Virus (HCV) [3].

Company Overview - Atea Pharmaceuticals (AVIR) is focused on developing antiviral treatments for hepatitis C (HCV) and hepatitis E (HEV) viruses [1] - The lead candidate for HCV treatment is bemnifosbuvir/ruzasvir (BEM/RZR), which is currently undergoing evaluation in two parallel phase 3 trials, one located in North America [1] Investment Insights - The investment style associated with Atea Pharmaceuticals includes a focus on clinical-stage biotech stocks, emphasizing both long-term ideas and event-driven trading [1] - The analyst's background in academia and medicine aids in evaluating the scientific fundamentals of biotech stocks, which is crucial for informed investment decisions [1]